CymaBay Therapeutics, Inc.

... ...
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -0.64%124.210.0%$2600.97m
BNGOBioNano Genomics, Inc. -13.68%7.890.0%$1548.32m
GILDGilead Sciences, Inc. 0.13%67.161.0%$694.65m
CRSPCRISPR Therapeutics AG 0.84%199.950.6%$578.00m
AMGNAmgen, Inc. 0.10%248.511.3%$557.98m
NVAXNovavax, Inc. 1.84%130.3592.9%$481.04m
ALXNAlexion Pharmaceuticals, Inc. 0.38%159.312.0%$476.25m
REGNRegeneron Pharmaceuticals, Inc. 0.40%536.002.7%$475.94m
ILMNIllumina, Inc. -0.05%390.003.5%$375.93m
SRPTSarepta Therapeutics, Inc. 1.68%98.4313.8%$346.41m
VRTXVertex Pharmaceuticals, Inc. 0.47%233.001.9%$345.76m
BIIBBiogen, Inc. 0.04%273.951.7%$332.52m
BNTXBioNTech SE -0.54%104.130.0%$316.39m
OCGNOcugen, Inc. 1.72%2.380.0%$313.45m
PACBPacific Biosciences of California, Inc. 0.00%40.207.4%$276.20m

Company Profile

CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.